Tiger Brokers

BUZZ- Artiva surges on US FDA's 'fast track' tag for cell therapy

Reuters
Oct 17
BUZZ- Artiva surges on US FDA's 'fast track' tag for cell therapy

** Shares of drug developer Artiva ARTV.O surge 102.5% to $5.57 premarket

** Co on Thursday said U.S. FDA granted fast track designation to its cell therapy AlloNK for treating refractory rheumatoid arthritis

** U.S. FDA's "fast track" tag aims to speed development and review of drugs for serious conditions with unmet medical need

** Refractory rheumatoid arthritis is a chronic joint disease

** Over 20 patients tested with AlloNK plus antibody therapy across autoimmune trials, including RA and lupus- ARTV

** Lupus is a chronic autoimmune disease where the body's immune system mistakenly attacks its own tissues and organs

** Co says safety data to highlight tolerability and ease-of-use

** Up to last close, stock down ~73%

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10